WholeReach · industry directory

Life Sciences

The companies that define the life sciences industry, each read on the same nine-check website rubric — a 0–100 score with the exact fixes — alongside the concepts, the developments and the questions that shape the field.

See the directoryGet your free score

The companies

24 companies in the life sciences industry, each graded on the nine things that decide whether a buyer or an AI assistant can find and trust them online. Open any name for the full write-up and the specific fixes.

70+ solid   45–69 gaps   under 45 costing customers

Sites we couldn’t reach

12 businesses whose website blocked our scanner — common when a site filters datacenter traffic, and not a sign the site is broken. A blocked site is never scored zero.

Who defines the life sciences market

The firms, funds and institutions that set the terms in life sciences — context, not local listings; never scored.

Life Sciences guides

Concepts

FDA promotional regulation

FDA reviews advertising and promotional labeling for regulated products — for prescription drugs through the Office of Prescription Drug Promotion (OPDP). Promotional material must be truthful, non-misleading, consistent with the approved labeling, and adequately substantiated. Enforcement arrives as untitled letters and warning letters, which are public.

On-label vs off-label promotion

A company may promote a product only for the uses in its FDA-approved or cleared labeling. Physicians may prescribe off-label; the manufacturer may not promote off-label. Scientific exchange, responses to unsolicited requests and certain payer communications are separate, narrowly defined channels.

Fair balance

Promotional material presenting benefit must present risk with comparable prominence and readability — not a footnote after a headline claim. The most common reason promotional pieces are cited.

Substantial evidence

The statutory standard for a drug efficacy claim: adequate and well-controlled investigations. It is why 'shown to improve outcomes' is a regulated assertion, not a marketing phrase, and why claims must be traceable to a specific trial or to the label.

510(k) vs De Novo vs PMA

Three device routes. A 510(k) demonstrates substantial equivalence to a legally marketed predicate. De Novo creates a new classification for a novel low-to-moderate-risk device with no predicate. PMA is the most demanding — an approval requiring valid scientific evidence of safety and effectiveness, typically for Class III devices.

IDE (Investigational Device Exemption)

The authorization allowing an unapproved device to be used in a clinical study to collect the safety and effectiveness data a PMA or De Novo needs. Significant-risk studies require FDA approval of the IDE plus IRB approval.

CE mark and EU MDR/IVDR

The European conformity route. The Medical Device Regulation and In Vitro Diagnostic Regulation replaced the older directives, raising clinical-evidence and post-market requirements sharply and routing most products through a Notified Body. A CE mark is not an FDA clearance and cannot be presented as one in US material.

LDT (laboratory developed test) and the FDA rule

A test designed, manufactured and used within a single CLIA-certified high-complexity laboratory. FDA historically exercised enforcement discretion; its 2024 final rule sought to phase LDTs into device regulation. A federal court vacated that rule in 2025 — so LDTs remain governed primarily through CLIA, with the policy question unresolved.

CLIA waiver

A CLIA-waived test is simple enough and carries a low enough risk of erroneous result that it may be run outside a high-complexity lab — in a clinic, pharmacy or at the point of care. Waiver dramatically widens the addressable market, and is granted by FDA on its own application track.

RUO (research use only) labeling

A product labeled 'For Research Use Only. Not for use in diagnostic procedures.' may not be promoted for clinical diagnostic use. Marketing an RUO product with clinical claims — or supporting customers who use it clinically — is the classic way a tools company creates regulatory exposure.

IVD (in vitro diagnostic)

A reagent, instrument or system intended for use in the diagnosis of disease from specimens taken from the body. IVDs are regulated as medical devices, so a diagnostic company lives under device rules — design control, QMS, MDR reporting — not drug rules.

Companion diagnostic (CDx)

A test that is essential to the safe and effective use of a corresponding therapeutic — identifying which patients should receive it. CDx and drug are typically co-developed and cross-referenced in each other's labeling, which links two regulatory timelines and two commercial organizations.

GxP (GMP, GLP, GCP)

The good-practice regulations: GMP governs manufacturing, GLP governs non-clinical safety studies, GCP governs clinical trial conduct. They are quality-system requirements enforced by inspection, and non-compliance can invalidate data an entire program depends on.

21 CFR Part 11

FDA's rule on electronic records and electronic signatures — audit trails, access controls, system validation and record integrity. It is the reason regulated software procurement is slow and the reason a general-purpose tool cannot simply be adopted for GxP data.

Design control

The mandated device development discipline: design inputs and outputs, review, verification, validation, transfer to manufacturing, change control and the design history file. Verification asks whether you built it right; validation asks whether you built the right thing for the user need.

QMS and ISO 13485

ISO 13485 is the international quality management system standard for medical devices; in the US, 21 CFR Part 820 was harmonized toward it as the Quality Management System Regulation. Certification is table stakes for selling into Europe and for most serious device partnerships.

MDR reporting (medical device reporting)

The obligation to report device-related deaths, serious injuries and certain malfunctions to FDA within defined timelines. Reports land in the public MAUDE database, where competitors, customers and journalists can read them.

Recall classes

FDA classifies recalls by risk: Class I where use could cause serious injury or death, Class II where injury is temporary or reversible, Class III where a violation is unlikely to cause harm. The class drives notification scope, public visibility and remediation cost.

Sunshine Act / Open Payments

Manufacturers of covered drugs and devices must report payments and transfers of value to physicians and teaching hospitals; CMS publishes them in a searchable database. Every dinner, honorarium, consulting fee and grant is public, which shapes how KOL relationships are structured.

Anti-Kickback Statute and speaker programs

A criminal statute prohibiting remuneration to induce or reward referrals of federally reimbursed items. Speaker programs, advisory boards, consulting arrangements and educational grants are the highest-risk activities; the HHS OIG has issued a special fraud alert specifically on speaker programs.

Preclinical and the IND

Preclinical work — pharmacology, ADME, GLP toxicology, CMC — builds the package supporting an Investigational New Drug application. Once the IND is filed and the 30-day review passes without a clinical hold, human dosing may begin. 'IND-enabling' is the industry's standard milestone language.

Phase I / II / III / IV

Phase I tests safety, tolerability and dose, usually in a small group. Phase II tests preliminary efficacy and dose-ranging in patients. Phase III is the large controlled trial supporting approval. Phase IV is post-approval, covering long-term safety, new populations and commitments made at approval.

Adaptive trial design

A protocol that prespecifies modifications based on accumulating data — dropping arms, reallocating randomization, re-estimating sample size, or moving seamlessly between phases. Prespecification is what separates an adaptive design from data-driven improvisation that invalidates the result.

Endpoint (primary vs secondary)

The prespecified outcome a trial measures. The primary endpoint is what the trial is powered for and what an approval and a claim rest on; secondary endpoints are supportive and, unless hierarchically tested, cannot carry a claim. A trial that misses its primary but 'hit' a secondary has not succeeded.

Powering

Sizing a trial so it has an adequate probability — conventionally 80–90% — of detecting a specified effect if it exists. Underpowered trials produce ambiguous results; overpowered ones waste patients and money. Power depends on effect size, variability and alpha.

ITT vs per-protocol

Intention-to-treat analyzes every randomized subject in the assigned arm regardless of what happened afterward, preserving randomization and giving the conservative, regulator-preferred estimate. Per-protocol analyzes only compliant completers and typically flatters the treatment.

DSMB / DMC

An independent Data Safety Monitoring Board reviews unblinded accumulating safety and efficacy data and may recommend continuing, modifying or stopping a trial. Its independence from the sponsor is the point, and its charter is written before the first patient is enrolled.

CRO and CDMO

A Contract Research Organization runs clinical and preclinical work for a sponsor — sites, monitoring, data management, biostatistics. A Contract Development and Manufacturing Organization develops and makes the product. Both let a company convert fixed cost into variable cost, and both create dependency risk that diligence probes.

Orphan drug designation

A designation for products treating rare diseases, generally under 200,000 US patients, carrying tax credits, fee waivers and seven years of market exclusivity on approval for the designated indication. Designation is not approval and must never be presented as evidence a product works.

Expedited pathways (fast track, breakthrough, accelerated approval)

FDA mechanisms for serious conditions: fast track gives more frequent interaction and rolling review; breakthrough therapy designation adds intensive guidance where early evidence suggests substantial improvement; accelerated approval permits approval on a surrogate endpoint with required confirmatory trials. All are process designations, not efficacy findings.

Priority review voucher

A transferable voucher — awarded for rare pediatric, tropical or medical countermeasure approvals — entitling the holder to a shortened FDA review of a future application. Vouchers are sold on an open market and have historically been a meaningful non-dilutive asset for small companies.

Biosimilar

A biologic highly similar to an approved reference product with no clinically meaningful differences; an interchangeable biosimilar meets an additional standard permitting pharmacy-level substitution in many states. Biosimilars are not generics — they require their own clinical program.

BLA vs NDA vs ANDA

A Biologics License Application covers biologics under the Public Health Service Act. A New Drug Application covers small molecules. An Abbreviated New Drug Application covers generics, relying on the reference product's safety and efficacy data plus bioequivalence.

Exclusivity and the patent cliff

Regulatory exclusivity (new chemical entity, orphan, pediatric, biologic) runs alongside patent life and blocks competing approvals for a set period. Loss of exclusivity produces the patent cliff — the revenue collapse when generics or biosimilars enter, which drives most of the industry's M&A and licensing behavior.

Freedom to operate

An opinion, based on a search of issued claims in the relevant jurisdictions, on whether commercializing a product would infringe someone else's patent. Distinct from patentability: you can hold a patent on something you cannot legally sell.

Tech transfer and Bayh-Dole

The Bayh-Dole Act lets universities and small businesses retain title to inventions made with federal funding, in exchange for disclosure, US-manufacturing preference and government march-in rights. It is why university tech-transfer offices exist and why most academic spinouts start with a license, not an assignment.

SBIR / STTR

Federal non-dilutive grant programs — Small Business Innovation Research and Small Business Technology Transfer, the latter requiring a research-institution partner. NIH is the largest life-science funder of both, and Phase I/Phase II awards are a standard early bridge.

Upfront, milestones and royalties

The three components of most licensing economics: cash at signing, payments triggered by development and sales achievements, and a percentage of net sales. Headline 'biodollars' totals add all milestones as if every one will be hit, which is why the upfront is the number that reveals real conviction.

Out-licensing

Granting another company rights to develop or commercialize your asset, often by territory or indication. It funds development without dilution but transfers control, and the diligence and reversion clauses matter more than the headline value.

KOL and MSL

A Key Opinion Leader is a clinician or researcher whose judgment shapes a field's adoption. A Medical Science Liaison is a field-based scientific role who engages KOLs non-promotionally. The medical/commercial firewall between MSLs and sales exists for regulatory reasons and is audited.

Formulary and payer coverage

A payer's list of covered drugs and its tiers, plus the utilization management — prior authorization, step therapy, quantity limits — attached to each. A P&T committee decision determines real-world access far more than a prescriber's preference does.

Reimbursement code (CPT / HCPCS)

The billing codes a procedure, test or product must have to be paid. New tests often start with an unlisted or PLA code and low or no payment; obtaining a category I CPT code and a favorable rate is frequently a multi-year commercial project of its own.

Coverage with evidence development

A CMS mechanism paying for an item or service only when the patient is enrolled in an approved study or registry, so coverage and evidence generation happen together. It is a partial win — revenue arrives, but with a data obligation attached.

Cost of goods per test

The fully loaded cost to produce one assay result — reagents, consumables, instrument depreciation, labor, QC, failed runs and repeats. Reimbursement rates are set externally, so in diagnostics the margin is won or lost almost entirely on the COGS side.

Assay validation

Establishing documented evidence that a test performs as intended: accuracy, precision, analytical sensitivity and specificity, reportable range, reference interval, interference and carryover. Analytical validation asks whether the assay measures the analyte; clinical validation asks whether the result means anything for the patient.

Sensitivity and specificity

Sensitivity is the proportion of true positives correctly identified; specificity is the proportion of true negatives correctly identified. Both are independent of prevalence — unlike positive and negative predictive value, which are not, which is why a highly specific test can still produce mostly false positives in a low-prevalence population.

LOD (limit of detection)

The lowest analyte concentration reliably distinguished from a blank at a stated probability, typically 95%. It is the headline analytical claim for molecular assays and must be established experimentally, per test and per specimen type — never estimated.

Cold chain

The temperature-controlled handling of biologics, vaccines, reagents and specimens from manufacture to use — 2–8°C, frozen, or cryogenic. Excursions are deviations requiring investigation and can destroy product value, so validated packaging, continuous monitoring and qualified couriers are part of the product, not logistics overhead.

What’s happening

• Artificial intelligence has moved from pitch-deck language into the actual discovery workflow — protein structure prediction after AlphaFold, generative chemistry, and machine-learning target identification are now standard tooling at large pharma and at platform companies. The unresolved question is evidentiary, not technical: what a regulator will accept as support when a model contributed to a decision. FDA issued a draft guidance in January 2025 on the use of AI to support regulatory decision-making for drugs and biological products, proposing a risk-based credibility-assessment framework, and has separately deployed generative AI internally for reviewer support. For content, the practical rule is unchanged — an AI-derived hypothesis is not evidence, and a model's output cannot substitute for a validated study. 2026-08 source ↗
• The Inflation Reduction Act's Medicare drug price negotiation is now reshaping pipeline decisions rather than merely revenue. The first cycle covered ten Part D drugs with negotiated maximum fair prices taking effect at the start of 2026, and a second cycle of selected drugs follows for 2027. The structural effect is the small-molecule/biologic asymmetry — small molecules become negotiation-eligible earlier than biologics — which has visibly pushed portfolio weight toward biologics and toward indications reaching Medicare volume later. Legislative proposals to equalize the timelines have been introduced but not enacted. 2026-08 source ↗
• Biosecurity has become a supply-chain question. The BIOSECURE Act, which would restrict federal contracting with named Chinese biotechnology providers, passed the US House in 2024 and has been reintroduced since without being enacted. The sourcing behavior changed anyway: sponsors began dual-sourcing and requalifying CDMO capacity in the US, Europe, Japan, Korea and India in anticipation, and Western CDMOs have expanded capacity against that demand. Tech transfer between manufacturing sites is expensive and slow, so this is a multi-year shift, not a switch. 2026-08 source ↗
• FDA's final rule bringing laboratory developed tests under device regulation — published in May 2024 with a phased four-stage implementation — was vacated in its entirety by the US District Court for the Eastern District of Texas in March 2025, in litigation brought by the American Clinical Laboratory Association and the Association for Molecular Pathology. LDTs consequently remain regulated primarily through CLIA. The policy question is unresolved rather than settled, and diagnostics companies are building regulatory strategies that survive either outcome. 2026-08 source ↗
• GLP-1 receptor agonists have restructured pharmaceutical revenue at a scale the industry has not seen in decades, concentrating growth in Novo Nordisk and Eli Lilly and pulling capital, manufacturing capacity and clinical attention toward metabolic disease. The knock-on effects are broad: fill-finish capacity shortages, multibillion-dollar US manufacturing commitments, an oral-formulation race, compounding and supply-shortage disputes, and payer coverage fights over obesity indications. For adjacent companies the practical consequence is competition for the same CDMO slots and the same injectable-device supply. 2026-08
• Biotech funding has recovered unevenly from the 2022–2023 contraction. Capital is available but concentrated — large rounds for late-stage clinical assets, platform companies with partnered validation and metabolic or obesity-adjacent programs, while preclinical and single-asset early-stage companies still face a difficult market. The IPO window reopens in bursts rather than steadily, and a meaningful share of exits now happen through acquisition by large pharma facing loss of exclusivity rather than through listing. 2026-08
• CPRIT — the Cancer Prevention and Research Institute of Texas, headquartered in Austin — remains the largest state cancer-research funding program in the country and the single most important reason Texas has built a life-science cluster at all. Created by constitutional amendment in 2007 and extended by voters in 2019 to a total authorization of $6 billion, it funds academic research, prevention programs and company product development, and its recruitment awards have brought several hundred principal investigators to Texas institutions. For a Texas life-science company, CPRIT product-development grants are the most consequential source of non-dilutive capital available. 2026-08
• Dell Medical School at UT Austin, which opened in 2016 as the first new medical school at a tier-one US research university in decades, has matured into a research-commercialization engine alongside UT Austin's College of Natural Sciences and Cockrell School. UT Austin's translational programs move faculty inventions toward company formation, and the university's expanding clinical and cancer-care partnerships give Austin something it previously lacked — an academic medical center capable of hosting trials locally rather than referring them to Houston or Dallas. 2026-08 source ↗
• Clinical trials have partly decentralized and permanently diversified their operating model. FDA finalized guidance on decentralized clinical trials in 2024, legitimizing remote visits, local labs, telehealth assessments and direct-to-patient shipment as protocol design choices rather than exceptions. The Food and Drug Omnibus Reform Act's requirement for diversity action plans on many pivotal studies pushed enrollment planning toward representativeness, though the guidance itself has been subject to policy reversal — so sponsors are designing for enrollment diversity as a scientific and payer expectation regardless of the regulatory posture in any given year. 2026-08 source ↗
• Pharmaceutical manufacturing is reshoring under direct policy pressure. A Section 232 national-security investigation into pharmaceutical imports opened in 2025, and the tariff threat that accompanied it produced a wave of multibillion-dollar US plant commitments from large pharmaceutical companies. New sterile-injectable, API and biologics capacity takes years to qualify, so announcements substantially precede output — but the direction is unambiguous, and it is reopening domestic CDMO and equipment demand that had migrated offshore. 2026-08 source ↗
• Austin's own life-science base is a molecular-diagnostics lineage that now operates under out-of-state parents. Luminex, the multiplexing and molecular-diagnostics company founded in Austin, was acquired by Italy's DiaSorin in 2021 and operates as part of DiaSorin while retaining substantial Austin operations. Asuragen, the Austin genetic-testing and molecular-controls company, was acquired by Bio-Techne in 2021. The pattern — build locally, exit to a strategic — is the defining feature of the Austin cluster and shapes what local talent and supplier ecosystems look like. 2026-08 source ↗
• Colossal Biosciences, headquartered in Dallas with Texas research operations, has become the highest-profile biotechnology company in the state, raising at multibillion-dollar valuations for de-extinction and species-preservation work built on ancient-DNA sequencing, comparative genomics and multiplex gene editing. Its scientific claims are contested within the field — whether an edited proxy organism constitutes a de-extincted species is a genuine dispute, not a settled result — but its funding and visibility have measurably raised Texas's profile with biotech investors and recruits. 2026-08 source ↗
• The research-tools and sequencing layer has been reordered by antitrust and geopolitics rather than by technology. Illumina completed its court-ordered divestiture of Grail in 2024 and subsequently faced restrictions on selling into China, while competition in high-throughput sequencing intensified from Chinese and startup entrants. For customers, the practical outcome is genuine price pressure and second-source options in a category that was effectively single-supplier for a decade. 2026-08 source ↗
• Loss of exclusivity on several of the industry's largest products before the end of the decade is driving an acquisition cycle in which large pharma buys clinical-stage assets to refill pipelines, at premiums that set the exit expectation for the whole sector. For small companies the implication is concrete: the buyer's diligence standard — clean data, defensible IP, a manufacturable process, a regulatory path already discussed with FDA — is the real product specification, and content that demonstrates those things reaches the audience that matters. 2026-08

Questions people ask

What is the difference between a 510(k), a De Novo and a PMA?

explain substantial equivalence to a predicate, the De Novo route for novel low-to-moderate risk devices with no predicate, and PMA's independent demonstration of safety and effectiveness -- and that the pathway sets what may later be claimed

What is the difference between 'FDA cleared' and 'FDA approved'?

cleared refers to 510(k) clearance, approved to PMA or a drug approval; say plainly that using them interchangeably in marketing copy is a misbranding risk, not a style choice

What does research use only labelling mean, and what may we not say about an RUO product?

an RUO product is not for use in diagnostic procedures; explain that claims, sales practices and even support materials suggesting clinical use can convert it into an unapproved device in FDA's view

What is a laboratory developed test and who regulates it?

explain that FDA's 2024 final rule bringing LDTs under device regulation was vacated in full by a federal court in March 2025, so LDTs remain regulated primarily through CLIA -- and that the policy question is unresolved rather than settled

What is the difference between CLIA certification and FDA clearance?

CLIA regulates the laboratory performing testing; FDA regulates the test as a product -- a lab can be fully CLIA-certified running a test that has no FDA clearance at all

What is off-label use, and why can a company not promote it?

explain that a clinician may prescribe off-label but the manufacturer's promotion is limited to the approved or cleared labelling, and that the limit applies to sales decks, conference booths and website copy alike

What is fair balance in promotional material?

explain that benefit claims must be accompanied by comparable presentation of risk information, and that the requirement follows the claim into every format including social posts

What is a companion diagnostic?

define it as a test required to select patients for a specific therapy, usually co-developed and co-labelled, and note the commercial consequence -- the diagnostic's fate is tied to the drug's

What is the difference between a CRO and a CDMO?

research and clinical execution versus development and manufacturing; explain that many sponsors use both and that the contracts and risks are entirely different

What are fast track, breakthrough and accelerated approval, and how do they differ?

distinguish process designations that add FDA interaction from accelerated approval's surrogate-endpoint basis with confirmatory-trial obligations, and warn that designation is not approval and must not be marketed as though it were

What is design control?

describe the documented loop -- user needs, design inputs, outputs, verification, validation, transfer, design history file -- and that it is the first thing an inspector asks to see

What is a Form 483 and how is it different from a warning letter?

a 483 lists an investigator's observations at the close of an inspection; a warning letter is the agency's formal position after review -- explain what each means for a customer doing supplier diligence

Is a biosimilar the same thing as a generic?

no -- explain highly similar rather than identical, the analytical and clinical comparison required, and the separate question of interchangeability

What is the difference between analytical validation and clinical validation?

analytical validation shows the assay measures the analyte reliably -- precision, LOD, interference; clinical validation shows the result means something for the patient; a test can pass the first and fail the second

Which regulatory pathway will my device take?

this depends on the specific intended use, risk classification and whether a predicate exists; explain how classification is determined and recommend a pre-submission with FDA rather than guessing in public

Can we claim our assay is more sensitive than a competitor's?

explain that a comparative performance claim needs head-to-head data on the same samples under a defined protocol and must be consistent with cleared labelling; describe the evidence required and refuse to bless the claim in the abstract

Watch

Run a life sciences company?

Get your free website score and the exact list of what to fix — no charge, no pitch. Claim your listing or ask for the full report.